Targeting the p300/CBP epigenetic pathway to overcome hormone therapy resistance in advanced prostate cancer

被引：0
|
作者：
Chen, Emily L.
Hawkey, Nathan
Thomas, Beatrice C.
Ware, Kathryn E.
Runyambo, Daniella
Caligiuri, Maureen
Wilker, Erik
Soderblom, Erik J.
Moseley, M. Arthur, III
Guichard, Sylvie M.
Armstrong, Andrew J.
Somarelli, Jason A.
机构：
来源：
MOLECULAR CANCER THERAPEUTICS | 2021年 / 20卷 / 12期
关键词：
D O I：
10.1158/1535-7163.TARG-21-P204
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P204
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Dysregulation of the p300/CBP histone acetyltransferases in human cancer
    Xu, Longxia
    Xuan, Hongwen
    Shi, Xiaobing
    EPIGENOMICS, 2025, 17 (03) : 193 - 208
  • [32] Designing p300/CBP histone acetyltransferase inhibitors for cancer
    Cole, Philip A.
    MOLECULAR CANCER THERAPEUTICS, 2013, 12 (11)
  • [33] Discovery of a peptide proteolysis-targeting chimera (PROTAC) drug of p300 for prostate cancer therapy
    Zhang, Dize
    Ma, Bohan
    Liu, Donghua
    Wu, Wei
    Zhou, Tianyang
    Gao, Yibo
    Yang, Cunli
    Jian, Yanlin
    Fan, Yizeng
    Qian, Yuchen
    Ma, Jian
    Gao, Yang
    Chen, Yule
    Xu, Shan
    Li, Lei
    EBIOMEDICINE, 2024, 105
  • [34] Expression of steroid hormone transporter, SLCO1B3, is mediated by a CBP/p300 regulatory mechanism in prostate cancer
    McCrea, E. M.
    Huang, P. A.
    Harris, E. M.
    Strope, J. D.
    Sissung, T. M.
    Price, D. K.
    Chau, C. H.
    Figg, W. D.
    ANNALS OF ONCOLOGY, 2017, 28
  • [35] Targeting Notch signaling pathway to overcome drug resistance for cancer therapy
    Wang, Zhiwei
    Li, Yiwei
    Ahmad, Aamir
    Azmi, Asfar S.
    Banerjee, Sanjeev
    Kong, Dejuan
    Sarkar, Fazlul H.
    BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2010, 1806 (02): : 258 - 267
  • [36] Targeting AMPK Signaling Pathway to Overcome Drug Resistance for Cancer Therapy
    Wang, Zhiyu
    Liu, Pengxi
    Chen, Qianjun
    Deng, Shigui
    Liu, Xiaoyan
    Situ, Honglin
    Zhong, Shaowen
    Hann, Swei
    Lin, Yi
    CURRENT DRUG TARGETS, 2016, 17 (08) : 853 - 864
  • [37] Inhibition of MITF transcriptional activity independent of targeting p300/CBP coactivators
    Vachtenheim, Jiri
    Sestakova, Blanka
    Tuhackova, Zdena
    PIGMENT CELL RESEARCH, 2007, 20 (01): : 41 - 51
  • [38] Targeting pancreatic cancer organoids with dual BET and CBP/P300 inhibitor NEO2734
    Radulovich, Nikolina
    Tamblyn, Laura
    Seo, Heewon
    Haibe-Kains, Benjamin
    Lupien, Mathieu
    Gilles, Francis
    Tsao, Ming S.
    CANCER RESEARCH, 2019, 79 (24)
  • [39] Epigenetic reprogramming by CBP/P300 bromodomain inhibition of triple-negative breast cancer and the immune microenvironment
    Yuan, Xueying
    Soth, Michael
    Zhao, Na
    Jones, Philip
    Rosen, Jeffrey
    CANCER RESEARCH, 2024, 84 (03)
  • [40] HISTONE DEACETYLASE (HDAC1) AND HISTONE ACETYLTRANSFERASE (CBP/P300) IN THE PATHOGENESIS OF PROSTATE CANCER
    Abbas, Ata
    Shukla, Sanjeev
    Umar, Saleem
    MacLennan, Gregory T.
    Gupta, Sanjay
    JOURNAL OF UROLOGY, 2009, 181 (04): : 393 - 393
12345